FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367305349> ?p ?o ?g. }

• W4367305349 abstract "<h3>Objective:</h3> To compare the utility of skin biopsy versus DaTscan in supporting a diagnosis of a synucleinopathy. <h3>Background:</h3> Though the diagnosis of synucleinopathies (Lewy Body Dementia, Parkinson’s disease, Multiple System Atrophy, Pure Autonomic Failure) is clinical, there are supportive tests that can aid in the diagnosis. SPECT imaging with DaTscan (Ioflupane 123-I SPECT) identifies pre-synaptic dopaminergic deficits, which helps distinguish neurodegenerative parkinsonian syndromes from non-dopamine deficiency disorders. Skin biopsy in identifies the presence of phosphorylated synuclein (p-syn) within cutaneous nerves, and can help distinguish synucleinopathies from other atypical parkinsonian syndromes and non-parkinsonian disorders. <h3>Design/Methods:</h3> 24 patients were identified that were seen in the movement disorders clinic for possible parkinsonism. All patients underwent a DaTscan and a skin biopsy (3 small punch biopsies in the cervical area, thigh and leg). DaTscan and skin biopsy results were compared to clinician’s suspected diagnosis (prior to testing, synucleinopathy vs other disorder) to assess diagnostic efficacy. <h3>Results:</h3> DaTscan results were congruent with clinician’s suspected diagnosis in 15/24 cases (62.5%). Skin biopsy results were congruent with clinician’s suspected diagnosis in 20/24 cases (83.3%). In two cases, the skin biopsy was positive for p-syn deposition where a synucleinopathy was not suspected. In 8 patients where the DaTscan was negative but clinician suspicion for a synucleinopathy was high, skin biopsies were positive. <h3>Conclusions:</h3> Skin biopsy had greater diagnostic accuracy than the DaTscan when compared to the clinician’s suspected pre-testing diagnosis. This suggests that performing skin biopsies (minimally invasive, lower cost, can be done in the office) may be of higher diagnostic utility than a DaTscan. <b>Disclosure:</b> Dr. Urval has nothing to disclose. Dr. Meytin has nothing to disclose. Dr. Dorfman has nothing to disclose. Dr. Lahrmann has nothing to disclose. Dr. Bortan has nothing to disclose. Dr. Dagostine has received personal compensation for serving as an employee of Adamas. Dr. Dagostine has received personal compensation for serving as an employee of Neurocrine. Dr. Dagostine has received personal compensation for serving as an employee of Boston Scientific. Dr. Dagostine has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Adamas. Dr. Dagostine has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurocrine. Dr. Dagostine has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Adamas. Dr. Dagostine has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Neurocrine. Dr. Duffy has stock in Meru Health. An immediate family member of Dr. Moro-de-Casillas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. An immediate family member of Dr. Moro-de-Casillas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Intuitive. The institution of Dr. Moro-de-Casillas has received research support from Davis Phinney Foundation. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Adamas. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Ipsen. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Kyowa Kirin. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merz. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurocrine. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sunovion. Dr. Machado has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. Dr. Kanchana has nothing to disclose. Dr. DeMarcaida has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. DeMarcaida has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. Dr. DeMarcaida has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Acorda. Dr. DeMarcaida has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Kyowa Kirin. The institution of Dr. DeMarcaida has received research support from Pharma2B. The institution of Dr. DeMarcaida has received research support from Neuroderm. The institution of Dr. DeMarcaida has received research support from Addex." @default.
• W4367305349 created "2023-04-29" @default.
• W4367305349 creator A5014659903 @default.
• W4367305349 creator A5016951801 @default.
• W4367305349 creator A5024502899 @default.
• W4367305349 creator A5027261499 @default.
• W4367305349 creator A5038363883 @default.
• W4367305349 creator A5040303328 @default.
• W4367305349 creator A5045115145 @default.
• W4367305349 creator A5048790172 @default.
• W4367305349 creator A5077441915 @default.
• W4367305349 creator A5082511985 @default.
• W4367305349 creator A5087061694 @default.
• W4367305349 date "2023-04-25" @default.
• W4367305349 modified "2023-09-30" @default.
• W4367305349 title "Clinical Utility of Skin Biopsy Compared to DaTscan in Diagnosing Synucleinopathies (P3-11.001)" @default.
• W4367305349 doi "https://doi.org/10.1212/wnl.0000000000202596" @default.
• W4367305349 hasPublicationYear "2023" @default.
• W4367305349 type Work @default.
• W4367305349 citedByCount "0" @default.
• W4367305349 crossrefType "proceedings-article" @default.
• W4367305349 hasAuthorship W4367305349A5014659903 @default.
• W4367305349 hasAuthorship W4367305349A5016951801 @default.
• W4367305349 hasAuthorship W4367305349A5024502899 @default.
• W4367305349 hasAuthorship W4367305349A5027261499 @default.
• W4367305349 hasAuthorship W4367305349A5038363883 @default.
• W4367305349 hasAuthorship W4367305349A5040303328 @default.
• W4367305349 hasAuthorship W4367305349A5045115145 @default.
• W4367305349 hasAuthorship W4367305349A5048790172 @default.
• W4367305349 hasAuthorship W4367305349A5077441915 @default.
• W4367305349 hasAuthorship W4367305349A5082511985 @default.
• W4367305349 hasAuthorship W4367305349A5087061694 @default.
• W4367305349 hasConcept C126838900 @default.
• W4367305349 hasConcept C142724271 @default.
• W4367305349 hasConcept C16005928 @default.
• W4367305349 hasConcept C2775934546 @default.
• W4367305349 hasConcept C2776525014 @default.
• W4367305349 hasConcept C2777440831 @default.
• W4367305349 hasConcept C2778548049 @default.
• W4367305349 hasConcept C2779134260 @default.
• W4367305349 hasConcept C2779483572 @default.
• W4367305349 hasConcept C2779734285 @default.
• W4367305349 hasConcept C2780439664 @default.
• W4367305349 hasConcept C2781449126 @default.
• W4367305349 hasConcept C71924100 @default.
• W4367305349 hasConceptScore W4367305349C126838900 @default.
• W4367305349 hasConceptScore W4367305349C142724271 @default.
• W4367305349 hasConceptScore W4367305349C16005928 @default.
• W4367305349 hasConceptScore W4367305349C2775934546 @default.
• W4367305349 hasConceptScore W4367305349C2776525014 @default.
• W4367305349 hasConceptScore W4367305349C2777440831 @default.
• W4367305349 hasConceptScore W4367305349C2778548049 @default.
• W4367305349 hasConceptScore W4367305349C2779134260 @default.
• W4367305349 hasConceptScore W4367305349C2779483572 @default.
• W4367305349 hasConceptScore W4367305349C2779734285 @default.
• W4367305349 hasConceptScore W4367305349C2780439664 @default.
• W4367305349 hasConceptScore W4367305349C2781449126 @default.
• W4367305349 hasConceptScore W4367305349C71924100 @default.
• W4367305349 hasLocation W43673053491 @default.
• W4367305349 hasOpenAccess W4367305349 @default.
• W4367305349 hasPrimaryLocation W43673053491 @default.
• W4367305349 hasRelatedWork W1501867320 @default.
• W4367305349 hasRelatedWork W1818662905 @default.
• W4367305349 hasRelatedWork W1967103811 @default.
• W4367305349 hasRelatedWork W1972577646 @default.
• W4367305349 hasRelatedWork W2043822937 @default.
• W4367305349 hasRelatedWork W2087115391 @default.
• W4367305349 hasRelatedWork W2142059703 @default.
• W4367305349 hasRelatedWork W2145955423 @default.
• W4367305349 hasRelatedWork W3154313988 @default.
• W4367305349 hasRelatedWork W4210278145 @default.
• W4367305349 isParatext "false" @default.
• W4367305349 isRetracted "false" @default.
• W4367305349 workType "article" @default.